Supernus Pharmaceuticals
Update in progressSUPN (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals, Inc. is a Rockville, Maryland-based biopharma focused on CNS diseases in the United States. It commercializes Qelbree (ADHD non-stimulant), GOCOVRI (Parkinson’s dyskinesia), Oxtellar XR (epilepsy), APOKYN (hypomobility in advanced PD), Trokendi XR (epilepsy and migraine prophylaxis), XADAGO (off episodes in PD), and MYOBLOC (cervical dystonia and sialorrhea). It also develops ONAPGO, SPN-817 (Phase 2 for epilepsy and related disorders), SPN-820 (Phase 2 resistant depression), and SPN-443 (Phase 1 stimulant). Markets through wholesalers and pharmacies; has a Navitor collaboration for SPN-820. Founded 2005.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!